Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144614 | 0.86 | TSHR (0.40) | TSHRTDP1ADRB2ADRB1ADRB3 | |
| SCHEMBL21113533 | 0.70 | TSHR (0.48) | TSHRTDP1ADRB2ADRB1ADRB3 | |
| SCHEMBL25144825 | 0.69 | ADRB2 (0.34) | ADRB2ADRB1ADRB3 | |
| SCHEMBL25144721 | 0.69 | ADRB2 (0.34) | ADRB2ADRB1ADRB3 | |
| SCHEMBL25144643 | 0.67 | ADRB2 (0.31) | ADRB2ADRB1ADRB3 | |
| SCHEMBL19034592 | 0.67 | ADRB2 (0.37) | ADRB2ADRB1ADRB3 | |
| SCHEMBL12285560 | 0.66 | TSHR (0.53) | TSHRADRB2ADRB1ADRB3 | |
| SCHEMBL5913624 | 0.64 | — | — | |
| SCHEMBL10285998 | 0.63 | TSHR (0.46) | TSHRTDP1MEN1CYP1A2KMT2A | |
| SCHEMBL4808933 | 0.63 | PRKCA (0.47) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119227-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | INTEGRATED DNA TECHNOLOGIES, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119227-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | RNGTT, SSU72, NSUN2 | TSHR 2212/4885TDP1 569/4885ADRB2 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.